Skip to content

Clinical trials

Observational Nasopharyngeal Carcinoma trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Nasopharyngeal Carcinoma Phase: Observational Country / region: China Clear all

68 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20051
20123
20152
20161
20175
20185
20194
20206
20215
20227
20239
202413
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status27
Recruiting21
Completed13
Active, not recruiting4
Not yet recruiting1
Enrolling by invitation1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University22
Nanfang Hospital, Southern Medical University5
Zhejiang Cancer Hospital4
Fujian Cancer Hospital3
Jiangxi Provincial Cancer Hospital3
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3
Zhongshan People's Hospital, Guangdong, China3
First Affiliated Hospital, Sun Yat-Sen University2
Fudan University2
Jiangsu Cancer Institute & Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Nasopharyngeal Carcinoma68
Epstein-Barr Virus Infections5
Malnutrition2
Nasopharyngeal Neoplasms2
Neoplasms2
Carotid Artery Diseases1
Cognitive Dysfunction1
Disease1
Genetic Predisposition to Disease1
Head and Neck Neoplasms1

Trials

Showing 1 to 25 of 68. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.